Inebilizumab-cdon Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Inebilizumab-cdon Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
45
Registered trials
70
Result records
5
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Inebilizumab-cdon can convert its Monoclonal antibody profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Inebilizumab-cdon (query alias: inebilizumab) |
|---|---|
| Modality / target | Monoclonal antibody; CD19; CD19 inhibitors, ADCC |
| Highest global status | Approved |
| Originator | Duke University |
| Active developers | Amgen, Inc., Amgen Europe BV, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
The MCP disease footprint includes Myasthenia Gravis, Immunoglobulin G4-Related Disease, AQP4-IgG positive Neuromyelitis optica spectrum disorder. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600119728 | Phase 4 | Completed | 60 | Relapse-free rate |
| NCT07598825 | Phase 3 | Not yet recruiting | 180 | Part 1: Number of Participants who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs of Interest at Week 26 |
| NCT07222553 | Phase 2 | Not yet recruiting | 15 | Maximum Plasma Concentration (Cmax) of Inebilizumab |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
LONG-TERM EFFICACY AND SAFETY OF INEBILIZUMAB IN IgG4-RELATED DISEASE: PRIMARY RESULTS FROM YEAR 1 OF THE OPEN LABEL PERIOD OF THE PHASE 3 MITIGATE TRIAL
Phase 3; n=107; evaluation: Positive. Reported fields: Adverse Event: COVID-19 = The most common adverse events (AEs) in the OLP were COVID-19, upper respiratory infection, cough, and influenza ; Adverse Event: COVID-19 = The most common adverse events (AEs) in the OLP were COVID-19, upper respiratory infection, cough, and influenza
IMMUNOGENICITY AND IMPACT OF ANTI-DRUG ANTIBODIES ON THE EFFICACY AND PHARMACOKINETICS OF INEBILIZUMAB IN MITIGATE, A PHASE 3 TRIAL IN IgG4-RELATED DISEASE
Phase 3; n=135; evaluation: Positive. Reported fields: Incidence of ADA = 5.0 Pts ; Incidence of ADA = 6.0 Pts
Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy and Pharmacodynamics in AChR+ Cohort (Week 52)
Phase 3; n=190; evaluation: Positive. Reported fields: ADA = 2.1 % ; ADA = 4.2 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Inebilizumab-cdon addresses Myasthenia Gravis, Immunoglobulin G4-Related Disease, AQP4-IgG positive Neuromyelitis optica spectrum disorder. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-12-12 | Amgen Completes Acquisition Of Horizon Therapeutics Plc | Approved | US$28,500.0M stated total |
| 2021-02-01 | Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. | Phase 3 | Financial terms not disclosed |
| 2019-10-08 | Mitsubishi will collaborate with Viela Bio to develop and market inebilizumab for NMOSD in Japan and other Asian regions. | Phase 3 | US$30.0M upfront; US$30.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
